Literature DB >> 16676010

Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines.

Lisa J Wood1, Lillian M Nail, April Gilster, Kerri A Winters, Collin R Elsea.   

Abstract

PURPOSE/
OBJECTIVES: To provide an overview of the evidence that supports a role for the proinflammatory cytokines interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) in the etiology of cancer chemotherapy-related symptoms. DATA SOURCES: Electronic nursing, psychology, and medicine databases; online meeting abstracts; and personal experimental observations. DATA SYNTHESIS: Substantial evidence implicates the proinflammatory cytokines IL-1beta, TNF-alpha, and IL-6 in the etiology of chemotherapy-related anorexia, cachexia, anemia, pain, sleep disturbance, fatigue, and depression.
CONCLUSIONS: Further investigation into the role of these cytokines in the genesis of chemotherapy-related symptoms is warranted. The development of appropriate animal models likely will be key to understanding the relationship among cancer chemotherapy, proinflammatory cytokines, and symptoms. IMPLICATIONS FOR NURSING: Nurses traditionally have been leaders in symptom management. The symptoms experienced by patients undergoing chemotherapy have a profound negative impact on quality of life and patients' ability to receive prescribed treatments. An understanding of potential mechanisms underlying the physiologic and behavioral consequences of chemotherapy administration will aid nurses in the development of interventions to effectively manage chemotherapy-related symptoms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16676010     DOI: 10.1188/06.ONF.535-542

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  43 in total

1.  Exercise, sleep quality, and mediators of sleep in breast and prostate cancer patients receiving radiation therapy.

Authors:  Lisa K Sprod; Oxana G Palesh; Michelle C Janelsins; Luke J Peppone; Charles E Heckler; M Jacob Adams; Gary R Morrow; Karen M Mustian
Journal:  Community Oncol       Date:  2010-10

2.  Understanding Symptom Burden in Patients With Advanced Cancer Living in Rural Areas.

Authors:  Stephanie Gilbertson-White; Yelena Perkhounkova; Seyedehtanaz Saeidzadeh; Maria Hein; Rachel Dahl; Andrean Simons-Burnett
Journal:  Oncol Nurs Forum       Date:  2019-07-01       Impact factor: 2.172

3.  In vitro and in vivo imaging of peptide-encapsulated polymer nanoparticles for cancer biomarker activated drug delivery.

Authors:  Gulsim K Kulsharova; Matthew B Lee; Felice Cheng; Munima Haque; Hyungsoo Choi; Kyekyoon Kim; William D O'Brien; G Logan Liu
Journal:  IEEE Trans Nanobioscience       Date:  2013-12       Impact factor: 2.935

Review 4.  Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies.

Authors:  Jennifer M Loftis; Marilyn Huckans; Benjamin J Morasco
Journal:  Neurobiol Dis       Date:  2009-11-26       Impact factor: 5.996

5.  Corticotropin releasing factor-1 receptor antagonism alters the biochemical, but not behavioral effects of repeated interleukin-1β administration.

Authors:  Clare J Wilhelm; Aaron Murphy-Crews; Daniel J Menasco; Marilyn S Huckans; Jennifer M Loftis
Journal:  Neuropharmacology       Date:  2011-08-04       Impact factor: 5.250

6.  Perceived cognitive function for breast cancer survivors: association of genetic and behaviorally related variables for inflammation.

Authors:  Jamie S Myers; Theresa A Koleck; Susan M Sereika; Yvette P Conley; Catherine M Bender
Journal:  Support Care Cancer       Date:  2017-03-01       Impact factor: 3.603

7.  Sleep-wake functioning along the cancer continuum: focus group results from the Patient-Reported Outcomes Measurement Information System (PROMIS(®)).

Authors:  Kathryn E Flynn; Rebecca A Shelby; Sandra A Mitchell; Maria R Fawzy; N Chantelle Hardy; Aatif M Husain; Francis J Keefe; Andrew D Krystal; Laura S Porter; Bryce B Reeve; Kevin P Weinfurt
Journal:  Psychooncology       Date:  2010-10       Impact factor: 3.894

8.  Early manifestation of mild cognitive impairment in B-cell non-Hodgkin's lymphoma patients receiving CHOP and rituximab-CHOP chemotherapy.

Authors:  Mohd Ashif Khan; Kamlesh Garg; Dinesh Bhurani; Nidhi Bharal Agarwal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-08-27       Impact factor: 3.000

9.  Pre-treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy.

Authors:  Lianqi Liu; Lavinia Fiorentino; Loki Natarajan; Barbara A Parker; Paul J Mills; Georgia Robins Sadler; Joel E Dimsdale; Michelle Rissling; Feng He; Sonia Ancoli-Israel
Journal:  Psychooncology       Date:  2009-02       Impact factor: 3.894

10.  A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122).

Authors:  Lawrence Berk; Jennifer James; Anna Schwartz; Eugen Hug; Anand Mahadevan; Michael Samuels; Lisa Kachnic
Journal:  Support Care Cancer       Date:  2008-02-22       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.